IMPORTANCE Shared gene variants in benign-malignant process pairs, such as BRAF mutations common to benign nevi and melanoma, are associated with differing phenotypic manifestations. Study of gene mechanisms underlying cherry angioma may uncover previously unknown disease relationships.
M any oncogenic mutations occur with high frequency in both benign and malignant proliferations (eg, BRAF V600E mutations in benign acquired melanocytic nevi and cutaneous melanoma 1 ), suggesting that oncogenetriggered signaling alone is insufficient to induce cancer. Furthermore, mutations in the same gene may yield pathologically distinct conditions, such as GNAQ mutations in uveal melanoma 2 and vascular anomalies such as Sturge-Weber syndrome. 3 Therapeutically targeting oncogenic drivers has been associated with significant response in cancer, but the roles of such genes in benign conditions are less clear. 1 Uncovering mutational patterns in benign counterparts of malignant processes may yield fresh insights into genomic mechanisms underlying their shared biology. The clinical profile of cherry angiomas (CAs)-mature endothelial cell proliferations 4 -is similar to that of other age-related benign entities, such as nevi, lentigines, and seborrheic keratoses. The genetic landscape of CAs has not been thoroughly described in the literature. Other than polymerase chain reaction-based evidence that supports a possible role for human herpesvirus 8-related genetic material in eruptive CAs, 5 little is known about the somatic mutations that underlie this cutaneous lesion. We thus sought to use next-generation sequencing to examine CA genetic alterations among a panel of 323 cancer-relevant genes.
Methods
Ten formalin-fixed, paraffin-embedded CA samples from biopsies taken between July 10, 2016, and January 23, 2018, from unrelated individuals (Table) were obtained from the archival tissue collection at the Massachusetts General Physicians Organization Dermatopathology Associates in Newton. Samples were subjected in 2 batches (batch A: 4 samples, patients 1-4, samples obtained on December 6, 2017, from biopsies performed from July 10, 2017, to November 13, 2017; batch B: 6 samples, patients 5-10, samples obtained on February 13, 2018, from biopsies performed from November 17, 2017, to January 23, 2018) to the sequencing pipeline covering a panel of 323 cancer-relevant genes (eMethods and eTable 1 in the Supplement). The dates from obtaining the first tissue banked samples to the receipt of the final sequencing data were December 6, 2017 to May 2, 2018. Of 234 total mutations, we excluded 167 likely germline variants based on the presence of a known singlenucleotide polymorphism annotation or high allele balance; 31 based on the presence of intronic mutations; and 17 BCR and NOTCH2 mutations based on low mapping quality and nonspecific neighboring mutations, indicating an unreliable region (eFigure 1 in the Supplement). Mutations were annotated with a functional impact score, the average of conservation and specificity scores, calculated using evolutionary conservation patterns. Because the conservation and specificity scores are both negative logarithmic functions, mathematically, the functional impact score can range from negative infinity to infinity. Biologically, scores lie within the range -4 and 6, with most scores falling between -2 and 4: higher scores indicate greater likelihood of a functional mutation or driver mutation. 6 Proportions of endothelial cell nuclei to total endothelial and keratinocyte nuclei were manually estimated on hematoxylineosin-stained slides (eFigure 2 in the Supplement). Additional details are provided in the eMethods in the Supplement. The Partners HealthCare Institutional Review Board determined that electronic medical record review and specimen collection were exempt from institutional review board approval and from obtaining written informed consent from patients. R statistical software, version 3.5.0 (R Foundation for Statistical Computing) was used for all statistical analyses. Significance was set at a P < .05; significance testing was 2-sided.
Results
Ten samples from 6 women and 4 men with a median age of 54 years (range, 26-79 years) (Table) revealed 19 somatic variants after excluding putative germline variants, low-quality calls, and potential artifacts (eTable 2 in the Supplement). Cherry angiomas in samples 1, 4, and 7 carried no mutations among the interrogated gene panel.
Only missense mutations in GNAQ (HGNC 4390), GNA11 (HGNC 4379), and NOTCH1 (HGNC 7881) had high mutational functional impact scores (a score ≥3.5) 6 ( Figure 1 and Figure 2 ).
GNAQ variants were the most frequent (40%), specifically the GNAQ Q209H mutation (samples 2 and 9), Q209R (sample 6), and R183G (sample 3). The GNA11 Q209H missense mutation was identified in sample 5, and the NOTCH1 C552Y missense variant in sample 10. The incidence of GNAQ and GNA11 mutations was 50% in both sequencing batches. Additional mutations occurring frequently in the samples (20%) were NF1 (HGNC 7765) nonsense variants (Q282 and E1694 in sample 2 and R440 in sample 3) and STAG2 (HGNC 11355) splice region variants (samples 2 and 8) and had uncertain functional significance. The mean (SEM) allele balance of GNAQ, GNA11, and NOTCH1 mutations was 7.2% (0.9%), and endothelial cell nuclei comprised a mean (SEM) of 28.7% (1.9%) of total (endothelial and keratinocyte) nuclei (Table) . Assuming mutation heterozygosity, the estimated tumor cellularity based on allelic frequency was 15% to 20%. Forty-two percent of base pair changes were C>T transitions at dipyrimidine (CT, TC, and TT) sites (eFigure 3 in the Supplement 
Discussion
We describe what is, to our knowledge, the first systematic interrogation of variants in a common vascular tumor, the CA. Our identification of GNAQ Q209, GNAQ R183, and GNA11 Q209 mutations in 50% of samples highlights a likely role of GNAQ and GNA11 variants in CA development. The GNAQ and GNA11, closely related large GTPases, mediate downstream signaling from G-protein-coupled receptors. Histologically, CAs are characterized by dilated vessels rather than dense cell infiltrates. 4 Thus, it is conceivable that GNAQ and GNA11 mutations may lead to aberrations in vessel formation rather than endothelial cell proliferation, which is consistent with these mutations being implicated in various types of vasculopathy, such as Sturge-Weber syndrome. 3 The mutations identified in this study suggest a possible genetic association of CAs with other entities. Mutations at both Q209 and R183 hot spots in GNAQ and GNA11 have been identified in uveal melanoma, 2,7 blue nevi, 2 and melanoma associated with blue nevus. 2 Mosaic mutations in GNAQ R183, GNAQ Q209, and GNA11 R183 have also been associated with phakomatosis pigmentovascularis, which comprises vascular and dermal pigmentary anomalies. 8 The Q209 position specifically is a known hot spot for single 9 and multifocal 10 congenital hemangioma, hepatic small-vessel neoplasms, 11 and anastomosing hemangioma. 12 In addition, the R183 position (but not Q209) is a hot spot for nonsyndromic port-wine birthmarks, 3 Sturge-Weber syndrome, 3 and endothelial capillary malformations. 13 Our data suggest involvement of both R183 and Q209 hot spots in CA development. R183 mutations have been proposed to activate the p38 mitogen-activated protein kinase (MAPK) pathway and Q209 mutations to activate p38 MAPK, c-Jun N-terminal kinase (JNK), and extracellular-signal-regulated kinase (ERK) pathways. Further study of these genetic overlaps may help unravel why heterogeneity of these hot spots is observed in some conditions, such as uveal melanoma and CA, but not in others, such as Sturge-Weber syndrome. We identified a high-functional impact score somatic NOTCH1 C552Y mutation not previously described in the literature. Notch intercellular signaling is known to play a crucial role in vascular development and physiology, with notch signaling pathway defects associated with inherited vascular disease.
14 However, given the presence of NOTCH1 in only 1 of the 10 samples in our study, this is a putative CA-associated finding requiring further supportive evidence (ie, similar mutations in more samples, further functional validation). We identified 2 samples (20%) with inactivating NF1 nonsense mutations. Cherry angiomas occur more frequently in persons with neurofibromatosis type 1 than in the general population, 15 suggesting a possible association between NF1 inactivation and CA pathogenesis.
Limitations
Our study has several important limitations. First, next-generation sequencing indiscriminately analyzes DNA from all cell types within specimens; thus, variants specific to angioma cells cannot be separated from those in other cells. To address this limitation, we estimated the angioma-to-total cell percentage as 28.7% (Table) , which is likely an upper bound given that stromal (nonkeratinocytic) nuclei could not be quantified. Thus, somatic angioma-specific heterozygous mutations would be expected to occur with an allele balance of at most 14.4% (28.7% divided by 2). The observed mean allele balance (7.2%) is near the expected allele balance, which supports, but does not prove, an endothelial cell origin for the observed mutations. Second, the sample number was limited given that benign CAs are readily recognized clinically and thus rarely sampled for biopsy. Therefore, these results should be viewed as pilot analyses. More samples could also guard against batch effects. We did address this potential artifact by performing sequencing in distinct cohorts. The GNAQ/GNA11 mutation incidence was 50% in each of the separate cohorts, supporting interbatch reliability. Future study with comprehensive sequencing of additional samples and prospective biopsy of several lesions on a single patient may help to strengthen the findings.
Conclusions
We suggest a possible role for GNAQ-and GNA11-mediated signaling in CA pathogenesis, a finding consistent with the genetic underpinnings of vascular anomalies. We observed both R183 and Q209 hot spot variants among CAs, suggesting that CAs are possibly on a shared genetic spectrum with vascular entities, such as congenital and anastomosing hemangiomas, capillary malformations, port-wine birthmarks, and SturgeWeber syndrome, and melanocytic growths, such as blue nevi, melanoma associated with blue nevus, and uveal melanoma. Missense somatic mutations in GNAQ, GNA11, and NOTCH1 were identified in regions of high mapping quality. bp Indicates base pair. 
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Online-Only Figures eFigure 1. Exclusion of suspected germline and unreliable variants
A, Allele balance threshold of 0.3 was used to exclude likely germline mutations. Additionally, mutations with a known dbSNP annotation were excluded. B, An identical BCR variant appeared in 8/10 samples, which is unusual given that these are ten unrelated individuals. Examination of the actual variant call indicated that the mutation resided within a poor-quality region. and is therefore a likely artifact. Light bands correspond to low mapping quality read (MAPQ) of <30. C, Similarly, an identical NOTCH2 deletion was also detected in 9/10 specimens. Examination by IGV also indicated multiple nonspecific deletions around this region.
eFigure 4. Structural variant analysis
A, Number of structural variants (deletions, duplications, tandem deletions, foldback inversions). B, Difference in structural variant number by presence of a GNAQ or GNA11 mutation (t-test, p = 0.174). C, Significant difference in structural variant number by sex (mean 401 in females, 207 in males, t-test, p < 0.01).
eMethods. Tissue Preparation, Sequencing, and Bioinformatics Pipeline
Cells and tissues. Electronic medical record (EMR) review and specimen collection were determined to be exempt from IRB approval by the Partners HealthCare Institutional Review Board (IRB letter: 2015P002698/MGH). All tissue samples were obtained at the Massachusetts General Physicians Organization Dermatopathology Associates formalin-fixed paraffin-embedded (FFPE) tissue bank. Details on tissue samples in this study are provided in Table  1 . Samples were processed in two batches: Batch A, n=4, subjects 1-4, and Batch B, n=6, subjects 5-10. The two batches independently underwent the processes described below in Genomic DNA, library prep and capture, and Sequencing and data analysis sections.
Genomic DNA, library prep and capture. After extraction using the Qiagen FFPE extraction kit, genomic DNA was quantified by Picogreen (Invitrogen) and quality was accessed using Genomic DNA Tape for the 2200 Tapestation (Agilent). DNA from each sample was sheared by sonication with the following conditions: Peak Incident Power 175, Duty Cycle 20%, Intensity 5, Cycles per Burst 200, and 120 seconds using Covaris E220 instrument (Covaris).
To ensure the proper fragment size, samples were checked on TapeStation using the DNA High Sensitivity kit (Agilent). The sheared DNA proceeded to library prep using KAPA library prep kit (KAPA) following the "with beads" manufacturer protocol. Briefly, this protocol consists of 3 enzymatic reactions for end repair, A-tailing and Adaptor ligation, followed by barcode insertion by PCR using KAPA HiFi polymerase (6 cycles). PCR primers were removed by using 1.8x volume of Agencourt AMPure PCR Purification kit (Agencourt Bioscience Corporation). At the end of the library prep, samples were analyzed on TapeStation to verify correct fragment size and to ensure the absence of extra bands. Samples were quantified using KAPA qPCR quantification kit. Equimolar amounts of DNA were pooled for capture (8-16 samples per pool). 323 genes that are clinically relevant in cancer were selected for capture. Global copy number selected areas were also captured. We designed biotin labeled probes with Roche Nimblegen for capturing target regions (all exons in those 323 genes plus copy number regions) and followed manufacture's protocol for the capture step. Briefly, DNA was pooled (8-16 samples), dried out and after addition of the capture reagents and probes, samples were incubated at 47°C on thermocycler with heated lid (57 o C) for 64-74 hours. The targeted regions were recovered using streptavidin beads and the streptavidin-biotin-probetarget complex was washed and another round of PCR amplification was performed according to manufacturer's protocol. The quality of each captured sample was analyzed on TapeStation using the DNA High Sensitivity kit and the enrichment was accessed by qPCR using specific primers designed by Roche Nimblegen. The cutoff for the enrichment was 50-fold minimum.
Sequencing and data analysis. The captured libraries were sequenced on a HiSeq 2000 (Illumina Inc., San Diego, CA, USA) on a version 3 TruSeq paired end flowcell according to manufacturer's instructions at a cluster density between 700 -1000 K clusters/mm2. Sequencing was performed on a HiSeq 2000 for 2 × 100 paired end reads with a 7 nt read for indexes using Cycle Sequencing v3 reagents (Illumina). The resulting BCL files containing the sequence data were converted into ".fastq.gz" files and individual libraries within the samples were demultiplexed using CASAVA 1.8.2 with no mismatches. All regions were covered by >20 reads. For data analysis, we aligned the T200 target-capture deep-sequencing data to human reference assembly hg19 using BWA 1 and removed duplicated reads using Picard 2 . We called single nucleotide variants (SNVs) and small indels using an in-house developed analysis pipeline 3 . We called copy number alterations using a previously published algorithm 4 , which reports gain or loss status of each exon. To understand the potential functional consequence of detected variants, we compared them with dbSNP, COSMIC 5 , and TCGA databases, and annotated them using MutationAssessor for functional impact score (FIS) calculation 6 . Scores were definied as: High FIS: above 3.5, Medium FIS: between 1.9 and 3.5, Low FIS: between 0.8 and 1.9, Neutral FIS: below 0.8.
Exclusion of non-somatic and low-quality variants:
Processed mutational data from both batches was aggregated. Variants with a low (<0.3) allele balance (AB) were considered as somatic mutations, while those with a high AB (>=0.3) were excluded for germline correction 7 (eFigure 1A). Thus, 167 variants were initially excluded from analysis as probable SNPs in the presence of a known dbSNP annotation and/or high AB. Of 67 remaining variants, 31 intron variants were excluded. An identical BCR missense variant present in 8/10 samples was excluded as a likely artifact given the low (<30) mapping quality scores (MAPQ) of this region. Additionally, an identical NOTCH2 deletion detected in 9/10 individuals was excluded as an unreliable deletion given its presence among multiple nonspecific neighboring deletions and substitutions (eFigure 1B and C).
Visual Tissue Composition Examination. Cherry angioma tissues were formalin fixed, paraffin embedded, cut, and stained with hematoxylin and eosin in standard fashion. The slides were then scanned using the Nanozoomer slide scanner and visualized with Nanozoomer software (Hamamatsu Photonics). One section per patient with a GNAQ, GNA11, or NOTCH1 mutation was selected for counting. Manual counts of angioma and keratinocyte nuclei were performed, and the proportion of angioma nuclei was estimated to be that of the total number of nuclei (keratinocyte plus endothelial cell). eTable 1. 323-gene panel subjected to targeted sequencing
